Essential thrombocytosis natural history, complications and prognosis

Essential thrombocytosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Epidemiology and Demographics
Risk Factors
Screening
Causes
Differentiating Essential thrombocytosis from other Diseases
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Essential thrombocytosis natural history, complications and prognosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Essential thrombocytosis natural history, complications and prognosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Essential thrombocytosis natural history, complications and prognosis
CDC on Essential thrombocytosis natural history, complications and prognosis
Essential thrombocytosis natural history, complications and prognosis in the news
Blogs on Essential thrombocytosis natural history, complications and prognosis
Directions to Hospitals Treating Essential thrombocytosis
Risk calculators and risk factors for Essential thrombocytosis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]

Overview

If left untreated, patients with essential thrombocytosis may progress to develop symptoms like headache, dizziness, vision disturbances, chest pain, intense burning pain in hands and/or feet (erythromelalgia), numbness and tingling of hands and feet, and priapism (persistent and painful erection of the penis) depending on the vessel occluded with the thrombus. Common complications of essential thrombocytosis include thrombotic events (DVT, cerebrovascular accidents,etc), bleeding (bruises, gum bleeds, epistaxis, etc), acute leukemia, and myelofibrosis. Prognosis is generally good, and the survival rate of patients is usually normal with regular medical supervision. However, the patient may rarely experience a leukemic conversion or develop myelofibrosis.

Natural history

• Essential thrombocytosis is usually asymptomatic.
• The symptoms arise from complications of essential thrombocytosis and may include but are not limited to headache, dizziness, vision disturbances, chest pain, intense burning pain in hands and/or feet (erythromelalgia), numbness and tingling of hands and feet and priapism (persistent and painful erection of the penis).
• Without treatment, patients with very high platelet counts will develop serious complications from vascular occlusion and/or bleeding.
• Rarely some cases progress to fatal leukemia or may develop myelofibrosis.

Complications

• Some of the complications from essential thrombocytosis are as follows:
  • Thrombotic events
    • Pulmonary embolism
    • DVT
    • Cerebrovascular accidents (CVA)
    • Myocardial infarction
  • Bleeding
    • Bruises
    • Gum bleeds
    • Epistaxis
  • Acute leukemia
  • Myelofibrosis
• Complications may occur in pregnant patients with essential thrombocytosis. High platelet counts cause placental infarction and places the fetus at a higher risk than the mother. The complications may include the following:
  • Increased risk of thrombosis
  • Increased risk of spontaneous miscarriage
  • IUGR
  • Preterm labor
  • Placental abruption

Prognosis

• Essential thrombocytosis is associated with a good prognosis if medically supervised on a regular basis.
• Most of the patients remain asymptomatic for a long time and are diagnosed on routine blood tests or when tested for other conditions. Although some patients with very high counts may present with severe hemorrhagic or thombotic events needing treatment.
• Rarely the disease may progress to acute leukemia or myelofibrosis.

References

Template:WikiDoc Sources